References
- 1. Spaander MC, van Buuren HR, Janssen HL. Review article: the management of non-cirrhotic non-malignant portal vein thrombosis and concurrent portal hypertension in adults. Aliment Pharmacol Ther. 2007;Suppl 2:203-9.
- 2. Khare R, Sikora SS, Srikanth G et al. Extrahepatic portal venous obstruction and obstructive jaundice: approach to management. J Gastroenterol Hepatol. 2005;20(1):56-61.
- 3. Smalberg JH, Arends LR, Valla DC et al. Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood. 2012;120:4921-28.
- 4. Webb LJ, Sherlock S. The aetiology, presentation and natural history of extra-hepatic portal venous obstruction. Q J Med. 1979;48(192):627–39.
- 5. Wani ZA, Bhat RA, Bhadoria AS, Maiwall R. Extrahepatic Portal Vein Obstruction and Portal Vein Thrombosis in Special Situations: Need for a New Classification. Saudi J Gastroenterol. 2015;21(3):129-38.
- 6. Rosenberg JM, Tedesco M, Yao DC, Eisenberg D. Portal Vein Thrombosis Following Laparoscopic Sleeve Gastrectomy for Morbid Obesity. JSLS. 2012;16(4):639-43.
- 7. Primignani M, Martinelli I, Bucciarelli P et al. Risk factors for thrombophilia in extrahepatic portal vein obstruction. Hepatology. 2005;41(3):603-8.10.1002/hep.20591
- 8. Egesel T, Bűyűkasik Y, Dűndar SV et al. The role of natural anticoagulant deficiencies and factor V Leiden in the development of idiopathic portal vein thrombosis. J Clin Gastroenterol. 2000;30(1):66-71.
- 9. Colaizzo D, Amitrano L, Tiscia GL et al. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb Haemost. 2007;5(1):55-61.10.1111/j.1538-7836.2006.02277.x
- 10. Janssen H, Wijnhoud A, Haagsma E et al. Extrahepatic portal vein thrombosis: aetiology and determinants of survival. Gut. 2001;49(5):720–4.
- 11. Janssen HL, Leebeek FW - JAK2 mutation: The best diagnostic tool for myeloproliferative disease in splanchnic vein thrombosis? Hepatology. 2006;44(6):1391-3.
- 12. Janssen HL, Meinardi JR, Vleggaar FP et al. Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study. Blood. 2000;96(7):2364-8.
- 13. Hollingshead M, Burke CT, Mauro MA et al. Transcatheter thrombolytic therapy for acute mesenteric and portal vein thrombosis. J Vasc Interv Radiol. 2005;16(5):651-61.10.1097/01.RVI.0000156265.79960.86
- 14. Senzolo M, Tibbals J, Cholongitas E et al. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with and without cavernous transformation. Aliment Pharmacol Ther. 2006;23(6):767-75.
- 15. Primignani M, Barosi G, Bergamaschi G et al. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology. 2006;44(6):1528-34.
- 16. Vleggaar FP, van Buuren HR, Schalm SW. Endoscopic sclerotherapy for bleeding oesophagogastric varices secondary to extrahepatic portal vein obstruction in an adult Caucasian population. Eur J Gastroenterol Hepatol. 1998;10(1):81-5.
- 17. Denninger MH, Chaït Y, Casadevall N et al. Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. Hepatology. 2000;31(3):587–91.10.1002/hep.510310307
- 18. Valla D, Casadevall N, Huisse MG et al. Etiology of portal vein thrombosis in adults. A prospective evaluation of primary myeloproliferative disorders. Gastroenterology. 1988;94(4):1063-9.